UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000035908
Receipt number R000040886
Scientific Title A randomized, placebo-controlled, double-blind, parallel-group trial of observations of subjective and objective symptoms of eye fatigue and testing for improvement with the ingestion of bilberry extract
Date of disclosure of the study information 2019/02/18
Last modified on 2019/05/14 09:21:47

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A randomized, placebo-controlled, double-blind, parallel-group trial of observations of subjective and objective symptoms of eye fatigue and testing for improvement with the ingestion of bilberry extract

Acronym

A randomized, placebo-controlled, double-blind, parallel-group trial of observations of subjective and objective symptoms of eye fatigue and testing for improvement with the ingestion of bilberry extract

Scientific Title

A randomized, placebo-controlled, double-blind, parallel-group trial of observations of subjective and objective symptoms of eye fatigue and testing for improvement with the ingestion of bilberry extract

Scientific Title:Acronym

A randomized, placebo-controlled, double-blind, parallel-group trial of observations of subjective and objective symptoms of eye fatigue and testing for improvement with the ingestion of bilberry extract

Region

Japan


Condition

Condition

Healthy subjects

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The objective of this study is to investigate the effect of the test food on eye function in healthy Japanese men and women aged 25 years or older and 40 years or younger who have continued to consume the test food for 4 weeks.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Visual fatigue

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

4-week intake of the containing bilberry extract food of 1 capsule a day

Interventions/Control_2

4-week intake of the placebo food of 1 capsule a day

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

25 years-old <=

Age-upper limit

40 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Healthy Japanese men and women aged 25 to 40 years
2) People who feel tired of their eyes
3) Persons who routinely perform PC (PC) tasks or driving a car
4) Persons who have not undergone LASIK surgery (myopia correction surgery)
5) Subjects with uncorrected visual acuity of 0.2 or better at both eyes.
6) Persons who can be contacted by personal computers or smartphones
7) Persons with a BMI of 25 kg/m2 or less
8) People who can play games with smartphones for about 30 minutes
9) Subjects who are able to discontinue eye drops during the study period"

Key exclusion criteria

1) Patients who are currently receiving any medications or outpatient
2) Subjects currently undergoing exercise or diet therapy under the supervision of a physician
3) Persons with a history or current disease or complication of liver disease or serious diseases of renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological, or metabolic origin.
4) Persons who have been treated or had a history of chronic disease (arrhythmia, liver, kidney, cerebrovascular disease, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or other chronic diseases)
5) Persons who have had surgery of the digestive tract (appendicitis is allowed)
6) People who have pollinosis
7) Patients with ocular diseases other than refractive errors (hyperopia, myopia, astigmatism)
8) Persons with a history of drug allergy or food allergy
9) Those who wish to do so during pregnancy, lactation, or the study period.
10) Those who have received blood donations or vaccinations within the previous three months or who are scheduled to do so during the study period.
11) Persons who regularly consume health foods, supplements, and medicines that may affect eye function.
12) Persons who are in hospital due to mental disorders (depression etc.), sleeping disorders, etc., or who have a past medical history in the past.
13) Persons who are under treatment or have a history of alcohol dependence, drug dependence or drug abuser.
14) Person who is in shift work such as night work
15) Extremely irregular lifestyle, such as eating and sleeping
16) Current smokers
17) Subjects who have participated in other clinical trials or are currently participating in other clinical trials within the past 3 months of the date of informed consent.
18) Persons who have difficulty complying with the records of various surveys
19) Other persons for whom the principal investigator judges it inappropriate for the study.
"

Target sample size

36


Research contact person

Name of lead principal investigator

1st name Kosehira
Middle name
Last name Marie

Organization

Omnica Co.,Ltd

Division name

Research and development Dept.

Zip code

112-0002

Address

TN Koishikawa BLDG. 5F, 1-15-17 Koishikawa, Bunkyo-ku, Tokyo, JAPAN

TEL

03-5840-9815

Email

kosehira@omnica.co.jp


Public contact

Name of contact person

1st name Daisuke
Middle name
Last name Ochitani

Organization

HUMA R&D CORP

Division name

Clinical Development Division

Zip code

108-0014

Address

Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan

TEL

03-3431-1260

Homepage URL


Email

ochitani@huma-rd.co.jp


Sponsor or person

Institute

HUMA R&D CORP

Institute

Department

Personal name



Funding Source

Organization

Omnica Co.,Ltd

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Committees of Nihonbashi Egawa Clinic

Address

2F Kotobuki Build. 1-27-12 Yaesu Chuo-ku, Tokyo 103-0028 Japan

Tel

03-5204-0311

Email

jim@medipharma.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 02 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

37

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 01 Month 11 Day

Date of IRB

2019 Year 01 Month 15 Day

Anticipated trial start date

2019 Year 02 Month 14 Day

Last follow-up date

2019 Year 04 Month 06 Day

Date of closure to data entry

2019 Year 04 Month 08 Day

Date trial data considered complete

2019 Year 04 Month 28 Day

Date analysis concluded

2019 Year 08 Month 31 Day


Other

Other related information



Management information

Registered date

2019 Year 02 Month 18 Day

Last modified on

2019 Year 05 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040886


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name